bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Video 1 from Peroxisome Proliferator-Activated Receptor-γ Activation Inhibits Tumor Metastasis by Antagonizing Smad3-Mediated Epithelial-Mesenchymal Transition
Authors: Reka Ajaya Kumar , Kurapati Himabindu , Narala Venkata R. , Bommer Guido , Chen Jun , Standiford Theodore J. , Keshamouni Venkateshwar G.
Published: April 2023

Supplementary Video 1 from Peroxisome Proliferator-Activated Receptor-γ Activation Inhibits Tumor Metastasis by Antagonizing Smad3-Mediated Epithelial-Mesenchymal Transition
Supplementary Table S1 from Modulation of cell cycle and gene expression in pancreatic tumor cell lines by methionine deprivation (methionine stress): implications to the therapy of pancreatic adenocarcinoma
Authors: Kokkinakis Demetrius M. , Liu XiaoYan , Neuner Russell D.
Published: April 2023

Changes in gene expression under MET-stress in CAPAN1 and CFPAC1.
Supplementary Data from Shikonin circumvents cancer drug resistance by induction of a necroptotic death
Authors: Han Weidong , Li Ling , Qiu Shuang , Lu Qinghua , Pan Qiangrong , Gu Ying , Luo Jianhong , Hu Xun
Published: April 2023

Supplementary Data from Shikonin circumvents cancer drug resistance by induction of a necroptotic death
Supplementary Figure Legends and Methods from Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma
Authors: Augustine Christina K. , Jung Sin-Ho , Sohn Insuk , Yoo Jin Soo , Yoshimoto Yasunori , Olson John A. , Friedman Henry S. , Ali-Osman Francis , Tyler Douglas S.
Published: April 2023

Supplementary Figure Legends and Methods from Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma
Supplementary Figure 3 from Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma
Authors: Augustine Christina K. , Jung Sin-Ho , Sohn Insuk , Yoo Jin Soo , Yoshimoto Yasunori , Olson John A. , Friedman Henry S. , Ali-Osman Francis , Tyler Douglas S.
Published: April 2023

Supplementary Figure 3 from Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma
Supplementary Figure 2 from Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma
Authors: Augustine Christina K. , Jung Sin-Ho , Sohn Insuk , Yoo Jin Soo , Yoshimoto Yasunori , Olson John A. , Friedman Henry S. , Ali-Osman Francis , Tyler Douglas S.
Published: April 2023

Supplementary Figure 2 from Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma
Supplementary Data from Effects of Thymoquinone in the Expression of Mucin 4 in Pancreatic Cancer Cells: Implications for the Development of Novel Cancer Therapies
Authors: Torres Maria P. , Ponnusamy Moorthy P. , Chakraborty Subhankar , Smith Lynette M. , Das Srustidhar , Arafat Hwyda A. , Batra Surinder K.
Published: April 2023

Supplementary Data from Effects of Thymoquinone in the Expression of Mucin 4 in Pancreatic Cancer Cells: Implications for the Development of Novel Cancer Therapies
Supplementary Figure 9 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer
Authors: Nagji Alykhan S. , Cho Sang-Hoon , Liu Yuan , Lee Jae K. , Jones David R.
Published: April 2023

Supplementary Figure 9 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer
Supplementary Figure 3 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer
Authors: Nagji Alykhan S. , Cho Sang-Hoon , Liu Yuan , Lee Jae K. , Jones David R.
Published: April 2023

Supplementary Figure 3 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer
Supplementary Fig. S1 from Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer
Authors: Liu Dong , Kojima Toru , Ouchi Masaaki , Kuroda Shinji , Watanabe Yuichi , Hashimoto Yuuri , Onimatsu Hideki , Urata Yasuo , Fujiwara Toshiyoshi
Published: April 2023

Supplementary Fig. S1 from Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer
Supplementary Data from Trifluorothymidine Resistance Is Associated with Decreased Thymidine Kinase and Equilibrative Nucleoside Transporter Expression or Increased Secretory Phospholipase A2
Authors: Temmink Olaf H. , Bijnsdorp Irene V. , Prins Henk-Jan , Losekoot Nienke , Adema Auke D. , Smid Kees , Honeywell Richard J. , Ylstra Bauke , Eijk Paul P. , Fukushima Masakazu , Peters Godefridus J.
Published: April 2023

Supplementary Data from Trifluorothymidine Resistance Is Associated with Decreased Thymidine Kinase and Equilibrative Nucleoside Transporter Expression or Increased Secretory Phospholipase A2
Supplementary Data from The Quassinoid Derivative NBT-272 Targets Both the AKT and ERK Signaling Pathways in Embryonal Tumors
Authors: Castelletti Deborah , Fiaschetti Giulio , Di Dato Valeria , Ziegler Urs , Kumps Candy , De Preter Katleen , Zollo Massimo , Speleman Frank , Shalaby Tarek , De Martino Daniela , Berg Thorsten , Eggert Angelika , Arcaro Alexandre , Grotzer Michael A.
Published: April 2023

Supplementary Data from The Quassinoid Derivative NBT-272 Targets Both the AKT and ERK Signaling Pathways in Embryonal Tumors
Supplementary Table S1 from Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo
Authors: Kortenhorst Madeleine S.Q. , Isharwal Sumit , van Diest Paul J. , Chowdhury Wasim H. , Marlow Cameron , Carducci Michael A. , Rodriguez Ronald , Veltri Robert W.
Published: April 2023

Supplementary Table S1 from Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo
Supplementary Data from Schweinfurthin A Selectively Inhibits Proliferation and Rho Signaling in Glioma and Neurofibromatosis Type 1 Tumor Cells in a NF1-GRD–Dependent Manner
Authors: Turbyville Thomas J. , Gürsel Demirkan B. , Tuskan Robert G. , Walrath Jessica C. , Lipschultz Claudia A. , Lockett Stephen J. , Wiemer David F. , Beutler John A. , Reilly Karlyne M.
Published: April 2023

Supplementary Data from Schweinfurthin A Selectively Inhibits Proliferation and Rho Signaling in Glioma and Neurofibromatosis Type 1 Tumor Cells in a NF1-GRD–Dependent Manner
Supplementary Fig. S5 from SHP and Sin3A expression are essential for adamantyl-substituted retinoid-related molecule–mediated nuclear factor-κB activation, c-Fos/c-Jun expression, and cellular apoptosis
Authors: Farhana Lulu , Dawson Marcia I. , Xu Liping , Dannenberg Jan-Hermen , Fontana Joseph A.
Published: April 2023

Supplementary Fig. S5 from SHP and Sin3A expression are essential for adamantyl-substituted retinoid-related molecule–mediated nuclear factor-κB activation, c-Fos/c-Jun expression, and cellular apoptosis
Supplementary Fig. S2 from A selective small-molecule nuclear factor-κB inhibitor from a high-throughput cell-based assay for “activator protein-1 hits”
Authors: Kang Moon-Il , Henrich Curtis J. , Bokesch Heidi R. , Gustafson Kirk R. , McMahon James B. , Baker Alyson R. , Young Matthew R. , Colburn Nancy H.
Published: April 2023

Supplementary Fig. S2 from A selective small-molecule nuclear factor-κB inhibitor from a high-throughput cell-based assay for “activator protein-1 hits”
Supplementary Tables 1-3 from Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline Chemotherapy In vivo in Human Acute Myeloid Leukemia Models
Authors: Lal Deepika , Park Jennifer A. , Demock Kellie , Marinaro Joseph , Perez Amanda M. , Lin Mei-Hui , Tian Lili , Mashtare Terry J. , Murphy Michael , Prey Joshua , Wetzler Meir , Fetterly Gerald J. , Wang Eunice S.
Published: April 2023

Supplementary Tables 1-3 from Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline Chemotherapy In vivo in Human Acute Myeloid Leukemia Models
Supplementary Figures 1-6 from Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline Chemotherapy In vivo in Human Acute Myeloid Leukemia Models
Authors: Lal Deepika , Park Jennifer A. , Demock Kellie , Marinaro Joseph , Perez Amanda M. , Lin Mei-Hui , Tian Lili , Mashtare Terry J. , Murphy Michael , Prey Joshua , Wetzler Meir , Fetterly Gerald J. , Wang Eunice S.
Published: April 2023

Supplementary Figures 1-6 from Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline Chemotherapy In vivo in Human Acute Myeloid Leukemia Models
Supplementary Data from Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
Authors: Baffert Fabienne , Régnier Catherine H. , De Pover Alain , Pissot-Soldermann Carole , Tavares Gisele A. , Blasco Francesca , Brueggen Josef , Chène Patrick , Drueckes Peter , Erdmann Dirk , Furet Pascal , Gerspacher Marc , Lang Marc , Ledieu David , Nolan Lynda , Ruetz Stephan , Trappe Joerg , Vangrevelinghe Eric , Wartmann Markus , Wyder Lorenza , Hofmann Francesco , Radimerski Thomas
Published: April 2023

Supplementary Data from Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
Supplementary Fig. S3 from Atypical retinoids ST1926 and CD437 are S-phase-specific agents causing DNA double-strand breaks: significance for the cytotoxic and antiproliferative activity
Authors: Valli Claudia , Paroni Gabriela , Di Francesco Angela Maria , Riccardi Riccardo , Tavecchio Michele , Erba Eugenio , Boldetti Andrea , Gianni' Maurizio , Fratelli Maddalena , Pisano Claudio , Merlini Lucio , Antoccia Antonio , Cenciarelli Chiara , Terao Mineko , Garattini Enrico
Published: April 2023

Supplementary Fig. S3 from Atypical retinoids ST1926 and CD437 are S-phase-specific agents causing DNA double-strand breaks: significance for the cytotoxic and antiproliferative activity
Supplementary Figure Legends 1-3, Table Legend 1 from A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts
Authors: Wang Yaolin , Lipari Philip , Wang Xiaoying , Hailey Judith , Liang Lianzhu , Ramos Robert , Liu Ming , Pachter Jonathan A. , Bishop W. Robert , Wang Yan
Published: April 2023

Supplementary Figure Legends 1-3, Table Legend 1 from A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts
Supplementary Fig. S3 from Recombinant, refolded tetrameric p53 and gonadotropin-releasing hormone-p53 slow proliferation and induce apoptosis in p53-deficient cancer cells
Authors: LaFevre-Bernt Michelle , Wu Shili , Lin Xinli
Published: April 2023

Supplementary Fig. S3 from Recombinant, refolded tetrameric p53 and gonadotropin-releasing hormone-p53 slow proliferation and induce apoptosis in p53-deficient cancer cells
Supplementary Fig Legends from Recombinant, refolded tetrameric p53 and gonadotropin-releasing hormone-p53 slow proliferation and induce apoptosis in p53-deficient cancer cells
Authors: LaFevre-Bernt Michelle , Wu Shili , Lin Xinli
Published: April 2023

Supplementary Fig Legends from Recombinant, refolded tetrameric p53 and gonadotropin-releasing hormone-p53 slow proliferation and induce apoptosis in p53-deficient cancer cells
Figure 2 from Dual repair modulation reverses Temozolomide resistance in vitro
Authors: Barvaux Vincent A. , Ranson Malcolm , Brown Robert , McElhinney R. Stanley , McMurry T. Brian H. , Margison Geoffrey P.
Published: April 2023

Figure 2 from Dual repair modulation reverses Temozolomide resistance in vitro
Supplementary Fig. S2 from KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo
Authors: Hassig Christian A. , Symons Kent T. , Guo Xin , Nguyen Phan-Manh , Annable Tami , Wash Paul L. , Payne Joseph E. , Jenkins David A. , Bonnefous Céline , Trotter Carol , Wang Yan , Anzola John V. , Milkova Elena L. , Hoffman Timothy Z. , Dozier Sara J. , Wiley Brandon M. , Saven Alan , Malecha James W. , Davis Robert L. , Muhammad Jerry , Shiau Andrew K. , Noble Stewart A. , Rao Tadimeti S. , Smith Nicholas D. , Hager Jeffrey H.
Published: April 2023

Supplementary Fig. S2 from KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo
Supplementary Figure Legend from Antimitotic effect of the retinoid 4-oxo-fenretinide through inhibition of tubulin polymerization: a novel mechanism of retinoid growth–inhibitory activity
Authors: Appierto Valentina , Tiberio Paola , Cavadini Elena , Casalini Patrizia , Cappelletti Graziella , Formelli Franca
Published: April 2023

Supplementary Figure Legend from Antimitotic effect of the retinoid 4-oxo-fenretinide through inhibition of tubulin polymerization: a novel mechanism of retinoid growth–inhibitory activity
Supplementary Fig. S1 from AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer
Authors: Nie Biao , Shen Zan , Wen Jun-Bao , Wong Oscar Gee-Wan , Hsueh Wayne D. , Huo Long-Fei , Kung Hsiang-Fu , Jiang Bo , Lin Marie C.M.
Published: April 2023

Supplementary Fig. S1 from AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer
Supplementary Table 3 from SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer
Authors: Novotny-Diermayr Veronica , Sangthongpitag Kanda , Hu Chang Yong , Wu Xiaofeng , Sausgruber Nina , Yeo Pauline , Greicius Gediminas , Pettersson Sven , Liang Ai Leng , Loh Yung Kiang , Bonday Zahid , Goh Kee Chuan , Hentze Hannes , Hart Stefan , Wang Haishan , Ethirajulu Kantharaj , Wood Jeanette Marjorie
Published: April 2023

Supplementary Table 3 from SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer
Supplementary Fig. S4E from Antitumor activity of a membrane lytic peptide cyclized with a linker sensitive to membrane type 1-matrix metalloproteinase
Authors: Zhong Jieying , Chau Ying
Published: April 2023

Supplementary Fig. S4E from Antitumor activity of a membrane lytic peptide cyclized with a linker sensitive to membrane type 1-matrix metalloproteinase
Supplementary Fig. S4D from Antitumor activity of a membrane lytic peptide cyclized with a linker sensitive to membrane type 1-matrix metalloproteinase
Authors: Zhong Jieying , Chau Ying
Published: April 2023

Supplementary Fig. S4D from Antitumor activity of a membrane lytic peptide cyclized with a linker sensitive to membrane type 1-matrix metalloproteinase
Supplementary Fig. S4A from Antitumor activity of a membrane lytic peptide cyclized with a linker sensitive to membrane type 1-matrix metalloproteinase
Authors: Zhong Jieying , Chau Ying
Published: April 2023

Supplementary Fig. S4A from Antitumor activity of a membrane lytic peptide cyclized with a linker sensitive to membrane type 1-matrix metalloproteinase
Supplementary Data 5 from Specific Alterations of MicroRNA Transcriptome and Global Network Structure in Colorectal Carcinoma after Cetuximab Treatment
Authors: Ragusa Marco , Majorana Alessandra , Statello Luisa , Maugeri Marco , Salito Loredana , Barbagallo Davide , Guglielmino Maria Rosa , Duro Laura R. , Angelica Rosario , Caltabiano Rosario , Biondi Antonio , Di Vita Maria , Privitera Giuseppe , Scalia Marina , Cappellani Alessandro , Vasquez Enrico , Lanzafame Salvatore , Basile Francesco , Di Pietro Cinzia , Purrello Michele
Published: April 2023

Supplementary Data 5 from Specific Alterations of MicroRNA Transcriptome and Global Network Structure in Colorectal Carcinoma after Cetuximab Treatment
Supplementary Video 2 from Real-time Fluorescent Resonance Energy Transfer Analysis to Monitor Drug Resistance in Chronic Myelogenous Leukemia
Authors: Tunceroglu Ahmet , Matsuda Michiyuki , Birge Raymond B.
Published: April 2023

Supplementary Video 2 from Real-time Fluorescent Resonance Energy Transfer Analysis to Monitor Drug Resistance in Chronic Myelogenous Leukemia
Supplementary Tables 1-5 from Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability
Authors: Degenhardt Yan , Greshock Joel , Laquerre Sylvie , Gilmartin Aidan G. , Jing Junping , Richter Mark , Zhang Xiping , Bleam Maureen , Halsey Wendy , Hughes Ashley , Moy Christopher , Liu-Sullivan Nancy , Powers Scott , Bachman Kurtis , Jackson Jeffrey , Weber Barbara , Wooster Richard
Published: April 2023

Supplementary Tables 1-5 from Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability
Supplementary Figure 4 from Real-time Fluorescent Resonance Energy Transfer Analysis to Monitor Drug Resistance in Chronic Myelogenous Leukemia
Authors: Tunceroglu Ahmet , Matsuda Michiyuki , Birge Raymond B.
Published: April 2023

Supplementary Figure 4 from Real-time Fluorescent Resonance Energy Transfer Analysis to Monitor Drug Resistance in Chronic Myelogenous Leukemia
Supplementary Figure 2 from Real-time Fluorescent Resonance Energy Transfer Analysis to Monitor Drug Resistance in Chronic Myelogenous Leukemia
Authors: Tunceroglu Ahmet , Matsuda Michiyuki , Birge Raymond B.
Published: April 2023

This is a video file.
Supplementary from Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells
Authors: Morales Cristina , García Maria J. , Ribas Maria , Miró Rosa , Muñoz Mar , Caldas Carlos , Peinado Miguel A.
Published: April 2023

Supplementary from Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells
Supplementary Figures 1-2 from Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma
Authors: Ekshyyan Oleksandr , Rong Youhua , Rong Xiaohua , Pattani Kavita M. , Abreo Fleurette , Caldito Gloria , Chang John Kai Siung , Ampil Federico , Glass Jonathan , Nathan Cherie-Ann O.
Published: April 2023

Supplementary Figures 1-2 from Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma
Supplementary Table S1 from MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents
Authors: Cochrane Dawn R. , Spoelstra Nicole S. , Howe Erin N. , Nordeen Steven K. , Richer Jennifer K.
Published: April 2023

Supplementary Table S1 from MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents
Supplementary Data from Oligodeoxyribozymes That Cleave β-Catenin Messenger RNA Inhibit Growth of Colon Cancer Cells via Reduction of β-Catenin Response Transcription
Authors: Choi Bo-Ra , Gwak Jungsug , Kwon Hyun-Mi , Oh Sangtaek , Kim Kwang Pyo , Choi Woo-Hyung , Cho Yo-Han , Kim Dong-Eun
Published: April 2023

Supplementary Data from Oligodeoxyribozymes That Cleave β-Catenin Messenger RNA Inhibit Growth of Colon Cancer Cells via Reduction of β-Catenin Response Transcription
Supplementary Fig. S2 from Effect of autophagy on multiple myeloma cell viability
Authors: Hoang Bao , Benavides Angelica , Shi Yijiang , Frost Patrick , Lichtenstein Alan
Published: April 2023

Supplementary Fig. S2 from Effect of autophagy on multiple myeloma cell viability
Supplementary Figure Legends from Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor
Authors: Abouantoun Thamara J. , MacDonald Tobey J.
Published: April 2023

Supplementary Figure Legends from Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor
Supplementary Fig. S1 from Rapamycin inhibits multiple stages of c-Neu/ErbB2–induced tumor progression in a transgenic mouse model of HER2-positive breast cancer
Authors: Mosley Jonathan D. , Poirier John T. , Seachrist Darcie D. , Landis Melissa D. , Keri Ruth A.
Published: April 2023

Supplementary Fig. S1 from Rapamycin inhibits multiple stages of c-Neu/ErbB2–induced tumor progression in a transgenic mouse model of HER2-positive breast cancer
Supplementary Table 1 from An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells
Authors: Kwong Joseph , Kulbe Hagen , Wong Donald , Chakravarty Probir , Balkwill Fran
Published: April 2023

Supplementary Table 1 from An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells
Supplementary Figure Legends from Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer
Authors: Landen Charles N. , Goodman Blake , Katre Ashwini A. , Steg Adam D. , Nick Alpa M. , Stone Rebecca L. , Miller Lance D. , Mejia Pablo Vivas , Jennings Nicolas B. , Gershenson David M. , Bast Robert C. , Coleman Robert L. , Lopez-Berestein Gabriel , Sood Anil K.
Published: April 2023

Supplementary Figure Legends from Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer
Supplementary Figure 2 from Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer
Authors: Landen Charles N. , Goodman Blake , Katre Ashwini A. , Steg Adam D. , Nick Alpa M. , Stone Rebecca L. , Miller Lance D. , Mejia Pablo Vivas , Jennings Nicolas B. , Gershenson David M. , Bast Robert C. , Coleman Robert L. , Lopez-Berestein Gabriel , Sood Anil K.
Published: April 2023

Supplementary Figure 2 from Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer
Supplementary Fig. S1 from Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
Authors: Forni Claudia , Minuzzo Mario , Virdis Emanuela , Tamborini Elena , Simone Matteo , Tavecchio Michele , Erba Eugenio , Grosso Federica , Gronchi Alessandro , Aman Pierre , Casali Paolo , D'Incalci Maurizio , Pilotti Silvana , Mantovani Roberto
Published: April 2023

Supplementary Fig. S1 from Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
Supplementary Fig. S1 from Influence of small interfering RNA corresponding to ets homologous factor on senescence-associated modulation of prostate carcinogenesis
Authors: Park Chaehwa , Lee Inkyoung , Kang Won Ki
Published: April 2023

Supplementary Fig. S1 from Influence of small interfering RNA corresponding to ets homologous factor on senescence-associated modulation of prostate carcinogenesis
Supplementary Data from Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo
Authors: Liu Jun-Yan , Park See-Hyoung , Morisseau Christophe , Hwang Sung Hee , Hammock Bruce D. , Weiss Robert H.
Published: April 2023

Supplementary Data from Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo
Supplementary Table S1 from Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway
Authors: Thress Kenneth , MacIntyre Terry , Wang Haiyun , Whitston Dave , Liu Zhong-Ying , Hoffmann Ethan , Wang Tao , Brown Jeffrey L. , Webster Kevin , Omer Charles , Zage Peter E. , Zeng Lizhi , Zweidler-McKay Patrick A.
Published: April 2023

Supplementary Table S1 from Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway
Supplementary Data from Improved Antitumor Activity and Tumor Targeting of NH2-Terminal–Specific PEGylated Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand
Authors: Chae Su Young , Kim Tae Hyung , Park Kyeongsoon , Jin Cheng-Hao , Son Sohee , Lee Seulki , Youn Yu Seok , Kim Kwangmeyung , Jo Dong-Gyu , Kwon Ick Chan , Chen Xiaoyuan , Lee Kang Choon
Published: April 2023

Supplementary Data from Improved Antitumor Activity and Tumor Targeting of NH2-Terminal–Specific PEGylated Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand
Supplementary Fig. S2 from Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells
Authors: Zinner Ralph G. , Barrett Brittany L. , Popova Elmira , Damien Paul , Volgin Andrei Y. , Gelovani Juri G. , Lotan Reuben , Tran Hai T. , Pisano Claudio , Mills Gordon B. , Mao Li , Hong Waun K. , Lippman Scott M. , Miller John H.
Published: April 2023

Supplementary Fig. S2 from Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells
Supplementary Data from Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer
Authors: Buck Elizabeth , Gokhale Prafulla C. , Koujak Susan , Brown Eric , Eyzaguirre Alexandra , Tao Nianjun , Rosenfeld-Franklin Maryland , Lerner Lorena , Chiu M. Isabel , Wild Robert , Epstein David , Pachter Jonathan A. , Miglarese Mark R.
Published: April 2023

Supplementary Data from Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer
Supplementary Figures 1-7 from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
Authors: Zha Jiping , O'Brien Carol , Savage Heidi , Huw Ling-Yuh , Zhong Fiona , Berry Leanne , Lewis Phillips Gail D. , Luis Elizabeth , Cavet Guy , Hu Xiaolan , Amler Lukas C. , Lackner Mark R.
Published: April 2023

Supplementary Figures 1-7 from Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
Supplementary Figure 3 from Systemic Administration of Polymeric Nanoparticle-Encapsulated Curcumin (NanoCurc) Blocks Tumor Growth and Metastases in Preclinical Models of Pancreatic Cancer
Authors: Bisht Savita , Mizuma Masamichi , Feldmann Georg , Ottenhof Niki A. , Hong Seung-Mo , Pramanik Dipankar , Chenna Venugopal , Karikari Collins , Sharma Rajni , Goggins Michael G. , Rudek Michelle A. , Ravi Rajani , Maitra Amarnath , Maitra Anirban
Published: April 2023

Supplementary Figure 3 from Systemic Administration of Polymeric Nanoparticle-Encapsulated Curcumin (NanoCurc) Blocks Tumor Growth and Metastases in Preclinical Models of Pancreatic Cancer
Supplementary Tables 1-4 from Cucurbitacin I Suppressed Stem-Like Property and Enhanced Radiation-Induced Apoptosis in Head and Neck Squamous Carcinoma–Derived CD44+ALDH1+ Cells
Authors: Chen Yi-Wei , Chen Kuan-Hsuan , Huang Pin-I , Chen Yu-Chih , Chiou Guang-Yu , Lo Wen-Liang , Tseng Ling-Ming , Hsu Han-Sui , Chang Kuo-Wei , Chiou Shih-Hwa
Published: April 2023

Supplementary Tables 1-4 from Cucurbitacin I Suppressed Stem-Like Property and Enhanced Radiation-Induced Apoptosis in Head and Neck Squamous Carcinoma–Derived CD44+ALDH1+ Cells
Supplementary Data from DNA fingerprinting of the NCI-60 cell line panel
Authors: Lorenzi Philip L. , Reinhold William C. , Varma Sudhir , Hutchinson Amy A. , Pommier Yves , Chanock Stephen J. , Weinstein John N.
Published: April 2023

Supplementary Data from DNA fingerprinting of the NCI-60 cell line panel
Supplementary Figure 2 from The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
Authors: Kojima Kensuke , Burks Jared K. , Arts Janine , Andreeff Michael
Published: April 2023

Supplementary Figure 2 from The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
Supplementary Fig. S2 from Identification of a small molecule class to enhance cell-cell adhesion and attenuate prostate tumor growth and metastasis
Authors: Shah Girish V. , Muralidharan Anbalagan , Thomas Shibu , Gokulgandhi Mitan , Mudit Mudit , Khanfar Mohammad , El Sayed Khalid
Published: April 2023

Supplementary Fig. S2 from Identification of a small molecule class to enhance cell-cell adhesion and attenuate prostate tumor growth and metastasis
Supplementary Fig. S1 from Identification of a small molecule class to enhance cell-cell adhesion and attenuate prostate tumor growth and metastasis
Authors: Shah Girish V. , Muralidharan Anbalagan , Thomas Shibu , Gokulgandhi Mitan , Mudit Mudit , Khanfar Mohammad , El Sayed Khalid
Published: April 2023

Supplementary Fig. S1 from Identification of a small molecule class to enhance cell-cell adhesion and attenuate prostate tumor growth and metastasis
Supplementary Figure 1 from Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase
Authors: Gao Yuanyuan , Fotovati Abbas , Lee Cathy , Wang Michelle , Cote Gilbert , Guns Emma , Toyota Brian , Faury Damien , Jabado Nada , Dunn Sandra E.
Published: April 2023

Supplementary Figure 1 from Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase
Supplementary Data from Nutlin-3a Induces Cytoskeletal Rearrangement and Inhibits the Migration and Invasion Capacity of p53 Wild-Type Cancer Cells
Authors: Moran Diarmuid M. , Maki Carl G.
Published: April 2023

Supplementary Data from Nutlin-3a Induces Cytoskeletal Rearrangement and Inhibits the Migration and Invasion Capacity of p53 Wild-Type Cancer Cells
Supplementary Figure 3A from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Authors: Raynaud Florence I. , Eccles Suzanne A. , Patel Sonal , Alix Sonia , Box Gary , Chuckowree Irina , Folkes Adrian , Gowan Sharon , De Haven Brandon Alexis , Di Stefano Francesca , Hayes Angela , Henley Alan T. , Lensun Letitia , Pergl-Wilson Giles , Robson Anthony , Saghir Nahid , Zhyvoloup Alexander , McDonald Edward , Sheldrake Peter , Shuttleworth Stephen , Valenti Melanie , Wan Nan Chi , Clarke Paul A. , Workman Paul
Published: April 2023

Supplementary Figure 3A from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Supplementary Data from Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma
Authors: Gaspar Nathalie , Sharp Swee Y. , Eccles Suzanne A. , Gowan Sharon , Popov Sergey , Jones Chris , Pearson Andrew , Vassal Gilles , Workman Paul
Published: April 2023

Supplementary Data from Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma
Supplementary Figure 1 from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Authors: Raynaud Florence I. , Eccles Suzanne A. , Patel Sonal , Alix Sonia , Box Gary , Chuckowree Irina , Folkes Adrian , Gowan Sharon , De Haven Brandon Alexis , Di Stefano Francesca , Hayes Angela , Henley Alan T. , Lensun Letitia , Pergl-Wilson Giles , Robson Anthony , Saghir Nahid , Zhyvoloup Alexander , McDonald Edward , Sheldrake Peter , Shuttleworth Stephen , Valenti Melanie , Wan Nan Chi , Clarke Paul A. , Workman Paul
Published: April 2023

Supplementary Figure 1 from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Supplementary Figure 4 from Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
Authors: Hirai Hiroshi , Iwasawa Yoshikazu , Okada Megumu , Arai Tsuyoshi , Nishibata Toshihide , Kobayashi Makiko , Kimura Toshifumi , Kaneko Naoki , Ohtani Junko , Yamanaka Kazunori , Itadani Hiraku , Takahashi-Suzuki Ikuko , Fukasawa Kazuhiro , Oki Hiroko , Nambu Tadahiro , Jiang Jian , Sakai Takumi , Arakawa Hiroharu , Sakamoto Toshihiro , Sagara Takeshi , Yoshizumi Takashi , Mizuarai Shinji , Kotani Hidehito
Published: April 2023

Supplementary Figure 4 from Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
Supplementary Table S2 from Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes
Authors: Shkreta Lulzim , Froehlich Ulrike , Paquet Éric R. , Toutant Johanne , Elela Sherif Abou , Chabot Benoit
Published: April 2023

Supplementary Table S2 from Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes
Supplementary Data from ClC-3 expression enhances etoposide resistance by increasing acidification of the late endocytic compartment
Authors: Weylandt Karsten H. , Nebrig Maxim , Jansen-Rosseck Nils , Amey Joanna S. , Carmena David , Wiedenmann Bertram , Higgins Christopher F. , Sardini Alessandro
Published: April 2023

Supplementary Data from ClC-3 expression enhances etoposide resistance by increasing acidification of the late endocytic compartment
Supplementary Table 1 from Knockdown of Inwardly Rectifying Potassium Channel Kir2.2 Suppresses Tumorigenesis by Inducing Reactive Oxygen Species–Mediated Cellular Senescence
Authors: Lee Inkyoung , Park Chaehwa , Kang Won Ki
Published: April 2023

Supplementary Table 1 from Knockdown of Inwardly Rectifying Potassium Channel Kir2.2 Suppresses Tumorigenesis by Inducing Reactive Oxygen Species–Mediated Cellular Senescence
Supplementary Figure Legends from Knockdown of Inwardly Rectifying Potassium Channel Kir2.2 Suppresses Tumorigenesis by Inducing Reactive Oxygen Species–Mediated Cellular Senescence
Authors: Lee Inkyoung , Park Chaehwa , Kang Won Ki
Published: April 2023

Supplementary Figure Legends from Knockdown of Inwardly Rectifying Potassium Channel Kir2.2 Suppresses Tumorigenesis by Inducing Reactive Oxygen Species–Mediated Cellular Senescence
Supplementary Fig. S1 from Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans
Authors: Huang R. Stephanie , Duan Shiwei , Kistner Emily O. , Hartford Christine M. , Dolan M. Eileen
Published: April 2023

Supplementary Fig. S1 from Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans
Supplementary Figure Legends from Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer
Authors: Ren Hening , Chu Zuoming , Mao Li
Published: April 2023

Supplementary Figure Legends from Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer
Supplementary Fig. from Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer
Authors: Ren Hening , Chu Zuoming , Mao Li
Published: April 2023

Supplementary Fig. from Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer
Supplementary Data from Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A
Authors: Kuznetsov Galina , Xu Qunli , Rudolph-Owen Lori , TenDyke Karen , Liu Junke , Towle Murray , Zhao Nanding , Marsh Joanne , Agoulnik Sergei , Twine Natalie , Parent Lana , Chen Zhihong , Shie Jue-Lon , Jiang Yimin , Zhang Huiming , Du Hong , Boivin Roch , Wang Yuan , Romo Daniel , Littlefield Bruce A.
Published: April 2023

Supplementary Data from Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A
Supplementary Table S3 from Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
Authors: Kumar Rakesh , Knick Victoria B. , Rudolph Sharon K. , Johnson Jennifer H. , Crosby Renae M. , Crouthamel Ming-Chih , Hopper Teresa M. , Miller Charles G. , Harrington Laura E. , Onori James A. , Mullin Robert J. , Gilmer Tona M. , Truesdale Anne T. , Epperly Andrea H. , Boloor Amogh , Stafford Jeffrey A. , Luttrell Deirdre K. , Cheung Mui
Published: April 2023

Supplementary Table S3 from Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
Supplementary Table S2 from Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
Authors: Kumar Rakesh , Knick Victoria B. , Rudolph Sharon K. , Johnson Jennifer H. , Crosby Renae M. , Crouthamel Ming-Chih , Hopper Teresa M. , Miller Charles G. , Harrington Laura E. , Onori James A. , Mullin Robert J. , Gilmer Tona M. , Truesdale Anne T. , Epperly Andrea H. , Boloor Amogh , Stafford Jeffrey A. , Luttrell Deirdre K. , Cheung Mui
Published: April 2023

Supplementary Table S2 from Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
Supplementary Fig. S1 from Orphan G protein–coupled receptor GPR56 plays a role in cell transformation and tumorigenesis involving the cell adhesion pathway
Authors: Ke Ning , Sundaram Roshni , Liu Guohong , Chionis John , Fan Wufang , Rogers Cheryl , Awad Tarif , Grifman Mirta , Yu Dehua , Wong-Staal Flossie , Li Qi-Xiang
Published: April 2023

Supplementary Fig. S1 from Orphan G protein–coupled receptor GPR56 plays a role in cell transformation and tumorigenesis involving the cell adhesion pathway
Supplementary Table from Suppression of cervical carcinoma cell growth by intracytoplasmic codelivery of anti-oncoprotein E6 antibody and small interfering RNA
Authors: Courtête Jérôme , Sibler Annie-Paule , Zeder-Lutz Gabrielle , Dalkara Deniz , Oulad-Abdelghani Mustapha , Zuber Guy , Weiss Etienne
Published: April 2023

Supplementary Table from Suppression of cervical carcinoma cell growth by intracytoplasmic codelivery of anti-oncoprotein E6 antibody and small interfering RNA
Supplementary Fig. S7 from Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells
Authors: Weisberg Ellen , Kung Andrew L. , Wright Renee D. , Moreno Daisy , Catley Laurie , Ray Arghya , Zawel Leigh , Tran Mary , Cools Jan , Gilliland Gary , Mitsiades Constantine , McMillin Douglas W. , Jiang Jingrui , Hall-Meyers Elizabeth , Griffin James D.
Published: April 2023

Supplementary Fig. S7 from Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells
Supplementary Fig. S3 from Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells
Authors: Weisberg Ellen , Kung Andrew L. , Wright Renee D. , Moreno Daisy , Catley Laurie , Ray Arghya , Zawel Leigh , Tran Mary , Cools Jan , Gilliland Gary , Mitsiades Constantine , McMillin Douglas W. , Jiang Jingrui , Hall-Meyers Elizabeth , Griffin James D.
Published: April 2023

Supplementary Fig. S3 from Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells
Data from Effects of Thymoquinone in the Expression of Mucin 4 in Pancreatic Cancer Cells: Implications for the Development of Novel Cancer Therapies
Authors: Torres Maria P. , Ponnusamy Moorthy P. , Chakraborty Subhankar , Smith Lynette M. , Das Srustidhar , Arafat Hwyda A. , Batra Surinder K.
Published: April 2023

Abstract
Pancreatic cancer is one of the most lethal cancers in the world, as it continues to be resistant to any therapeutic approaches. The high molecular weight glycoprotein mucin 4 (MUC4) is aberrantly expressed in pancreatic cancer and contributes to the regulation of differentiation, proliferation, metastasis, and the chemoresistance of pancreatic cancer cells. The absence of its expression in the normal pancreatic ductal cells makes MUC4 a promising target for novel cancer therapeutics. Natural products have been widely investigated as potential candidates in cancer therapies, and thymoquinone (TQ), extracted from the seeds of Nigella sativa, has shown excellent antineoplastic properties in some systems. In the present study, we evaluated the effect of TQ on pancreatic cancer cells and specifically investigated its effect on MUC4 expression. The MUC4-expressing pancreatic cancer cells FG/COLO357 and CD18/HPAF were incubated with TQ, and in vitro functional assays were done. The results obtained indicate that treatment with TQ downregulated MUC4 expression through the proteasomal pathway and induced apoptosis in pancreatic cancer cells by the activation of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase pathways. In agreement with previous studies, the decrease in MUC4 expression correlated with an increase in apoptosis, decreased motility, and decreased migration of pancreatic cancer cells. MUC4 transient silencing studies showed that c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase pathways are activated in pancreatic cancer cells, indicating that the activation of these pathways by TQ is directly related to the MUC4 downregulation induced by the drug. Overall, TQ has potential for the development of novel therapies against pancreatic cancer. Mol Cancer Ther; 9(5); 1419–31. ©2010 AACR.
Data from Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation
Authors: Lagas Jurjen S. , van Waterschoot Robert A.B. , Sparidans Rolf W. , Wagenaar Els , Beijnen Jos H. , Schinkel Alfred H.
Published: April 2023

Abstract
Sorafenib is a second-generation, orally active multikinase inhibitor that is approved for the treatment of patients with advanced renal cell carcinoma and patients with unresectable hepatocellular carcinoma. We studied active transport of sorafenib in MDCK-II cells expressing human P-glycoprotein (P-gp/ABCB1) or ABCG2 (breast cancer resistance protein) or murine Abcg2. Sorafenib was moderately transported by P-gp and more efficiently by ABCG2 and Abcg2. Because sorafenib is taken orally, we orally administered sorafenib to wild-type, Abcb1a/1b−/−, Abcg2−/−, and Abcb1a/1b;Abcg2−/− mice, completely lacking functional Abcb1a/1b, Abcg2, or both, respectively, and we studied plasma pharmacokinetics and brain accumulation. The systemic exposure on oral administration was not different among all strains. However, brain accumulation was 4.3-fold increased in Abcg2−/− mice and 9.3-fold increased in Abcb1a/1b;Abcg2−/− mice. Moreover, when wild-type mice were treated with sorafenib in combination with the dual P-gp and ABCG2 inhibitor elacridar, brain accumulation was similar to that observed for Abcb1a/1b;Abcg2−/− mice. These results show that the brain accumulation of sorafenib is primarily restricted by ABCG2. This contrasts with previous studies using shared ABCG2 and P-gp substrates, which all suggested that P-gp dominates at the blood-brain barrier, and that an effect of ABCG2 is only evident when both transporters are absent. Interestingly, for sorafenib, it is the other way around, that is, ABCG2, and not P-gp, plays the dominant role in restricting its brain accumulation. Clinically, our findings may be relevant for the treatment of renal cell carcinoma patients with central nervous system relapses, as a dual ABCG2 and P-gp inhibitor might improve the central nervous system entry and thereby the therapeutic efficacy of sorafenib. Mol Cancer Ther; 9(2); 319–26
Data from JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia
Authors: Manthey Carl L. , Johnson Dana L. , Illig Carl R. , Tuman Robert W. , Zhou Zhao , Baker Judith F. , Chaikin Margery A. , Donatelli Robert R. , Franks Carol F. , Zeng Lee , Crysler Carl , Chen Yanmin , Yurkow Edward J. , Boczon Lisa , Meegalla Sanath K. , Wilson Kenneth J. , Wall Mark J. , Chen Jinsheng , Ballentine Shelley K. , Ott Heidi , Baumann Christian , Lawrence Danielle , Tomczuk Bruce E. , Molloy Christopher J.
Published: April 2023

Abstract
There is increasing evidence that tumor-associated macrophages promote the malignancy of some cancers. Colony-stimulating factor-1 (CSF-1) is expressed by many tumors and is a growth factor for macrophages and mediates osteoclast differentiation. Herein, we report the efficacy of a novel orally active CSF-1 receptor (CSF-1R) kinase inhibitor, JNJ-28312141, in proof of concept studies of solid tumor growth and tumor-induced bone erosion. H460 lung adenocarcinoma cells did not express CSF-1R and were not growth inhibited by JNJ-28312141 in vitro. Nevertheless, daily p.o. administration of JNJ-28312141 caused dose-dependent suppression of H460 tumor growth in nude mice that correlated with marked reductions in F4/80+ tumor-associated macrophages and with increased plasma CSF-1, a possible biomarker of CSF-1R inhibition. Furthermore, the tumor microvasculature was reduced in JNJ-28312141–treated mice, consistent with a role for macrophages in tumor angiogenesis. In separate studies, JNJ-28312141 was compared with zoledronate in a model in which MRMT-1 mammary carcinoma cells inoculated into the tibias of rats led to severe cortical and trabecular bone lesions. Both agents reduced tumor growth and preserved bone. However, JNJ-28312141 reduced the number of tumor-associated osteoclasts superior to zoledronate. JNJ-28312141 exhibited additional activity against FMS-related receptor tyrosine kinase-3 (FLT3). To more fully define the therapeutic potential of this new agent, JNJ-28312141 was evaluated in a FLT3-dependent acute myeloid leukemia tumor xenograft model and caused tumor regression. In summary, this novel CSF-1R/FLT3 inhibitor represents a new agent with potential therapeutic activity in acute myeloid leukemia and in settings where CSF-1–dependent macrophages and osteoclasts contribute to tumor growth and skeletal events. [Mol Cancer Ther 2009;8(11):3151–61]
Intersectional Person Perception: A Scoping Review of Studies Investigating the Roles of Category Relationships and Cognitive Processes
Authors: Sternberg Béatrice , Badea Constantina , Rubin Mark
Published: April 2023

This review considered experimental studies that used an intersectional framework in order to examine (1) how perceived relationship between the categories in a given intersection impacts the perception of its members and (2) how intersectional person perception has been studied through different cognitive processes. A systematic search in databases identified 5,393 records, and a screening processes resulted in 43 articles reporting 110 studies. The way intersectional targets were cognitively processed depended on contextual factors as well as on the perceived relationship between intersected identities (e.g., perceived [in-]congruence between identities). Less prototypical intersectional targets (e.g., Black gay men) sometimes experienced intersectional invisibility, facing both relative advantages (e.g., being less associated with certain negative stereotypes), and disadvantages (e.g., being overlooked, less recognized) compared to more prototypical members of their constituent ingroups (e.g., Black people, gay men). Future work should incorporate observed exceptions to these patterns and expand the cultural context of analysis.